Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN V versus DYNACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN V versus DYNACIN.
ACHROMYCIN V vs DYNACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacteriostatic; binds reversibly to 30S ribosomal subunit, inhibits protein synthesis by blocking aminoacyl-tRNA binding to mRNA-ribosome complex.
Dynacin (minocycline) is a semi-synthetic tetracycline antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to mRNA-ribosome complex. It also has anti-inflammatory and neuroprotective effects via inhibition of microglial activation, matrix metalloproteinases, and p38 MAPK signaling.
250-500 mg orally every 6 hours
100 mg orally twice daily or 200 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 6-12 hours in patients with normal renal function; prolonged in renal impairment (up to 48-72 hours in anuria).
Terminal elimination half-life 18-24 hours; prolonged in renal impairment (up to 50 hours in severe insufficiency). Steady state achieved in 4-5 days.
Renal (60% unchanged in urine via glomerular filtration), biliary/fecal (40% as active drug and metabolites, with a portion undergoing enterohepatic recirculation).
Renal (40-50% unchanged), hepatic metabolism (30-40% as metabolites), fecal (<10%).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic